81624 Federal Register / Vol. 75, No. 248 / Tuesday, December 28, 2010 / Notices 

publishes abstracts of information 

collection requests under review by the 

Office of Management and Budget 

(OMB), in compliance with the 

Paperwork Reduction Act of 1995 (44 

U.S.C. Chapter 35). To request a copy of 

the clearance requests submitted to 

OMB for review, e-mail 

paperwork@hrsa.gov or call the HRSA 

Reports Clearance Office on (301) 443– 

1129. 

The following request has been 

submitted to the Office of Management 

and Budget for review under the 

Paperwork Reduction Act of 1995: 

Proposed Project: The National Health 

Service Corps (NHSC) Scholarship 

Program Application (OMB No. 0915– 

0146)—[Revision] 

The National Health Service Corps 

(NHSC) Scholarship Program provides 

the NHSC with the health professionals 

it requires to carry out its mission of 

providing primary health care to 

populations residing in areas of greatest 

need. Under this program, health 

professions students are awarded 

scholarships in return for service in a 

federally designated Health Professional 

Shortage Area (HPSA). Students are 

supported who are well qualified to 

participate in the NHSC Scholarship 

Program and who want to assist the 

NHSC in its mission, both during and 

after their period of obligated service. 

The NHSC Scholarship Program forms 

are used to collect relevant information 

necessary to make award 

determinations. Scholars are selected for 

these competitive awards based on the 

information provided in the application, 

forms, and supporting documentation. 

Awards are made to applicants who 

demonstrate a high potential for 

providing quality primary health care 

services in HPSAs. The program forms 

include the following: The NHSC 

Scholarship Program Application, 

Academic and Non-Academic 

Evaluation Letters (formerly Letters of 

Recommendation), the Authorization to 

Release Information, the Verification of 

Acceptance/Good Standing Report, the 

Receipt of Exceptional Financial Need 

Scholarship, the Verification Regarding 

Disadvantaged Background and the 

Acceptance/Declination Form. Also 

included are the Data Collection 

Worksheet, which is completed by the 

schools of program participants, the 

Deferment Request Form, which is 

completed by program participants and 

the Six-Month Service Obligation 

Verification Form, which is completed 

by program participants and their sites. 

The annual estimate of burden for 

applicants is as follows: 

Instrument Number of 

respondents 

Responses/ 

respondent 

Total 

responses 

Hours per 

response 

Total burden 

hours 

NHSC Scholarship Program Application ............................. 1,800 1 1,800 2.0 3,600 

Evaluation Letters ................................................................ 1,800 2 3,600 .50 1,800 

Authorization to Release Information .................................. 1,800 1 1,800 .10 180 

Verification of Acceptance/Good Standing Report .............. 1,800 1 1,800 .25 450 

Receipt of Exceptional Financial Need Scholarship ............ 100 1 100 .25 25 

Verification Regarding Disadvantaged Background ............ 300 1 300 .25 75 

Acceptance/Declination Form .............................................. 250 1 250 .10 25 

Total .............................................................................. ........................ ........................ 9,400 ........................ 6,155 

The annual estimate of burden for 

participants/schools/sites is as follows: 

Instrument Number of 

respondents 

Responses/ 

respondent 

Total 

responses 

Hours per 

response 

Total burden 

hours 

Data Collection Worksheet .................................................. 400 1 400 1.0 400 

Deferment Request Form .................................................... 60 1 60 .25 15 

Six-Month Service Obligation Verification Form .................. 700 2 1,400 .50 700 

Total .............................................................................. ........................ ........................ 1,860 ........................ 1,115 

Written comments and 

recommendations concerning the 

proposed information collection should 

be sent within 30 days of this notice to 

the OMB desk officer for HRSA, either 

by e-mail to 

OIRA_submission@omb.eop.gov or by 

fax to 202–395–6974. Please direct all 

correspondence to the ‘‘attention of the 

OMB desk officer for HRSA.’’ 

Dated: December 21, 2010. 

Robert Hendricks, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–32562 Filed 12–27–10; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Service 

Administration 

Advisory Committee on 

Interdisciplinary, Community-Based 

Linkages; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), notice is hereby given 

of the following meeting: 

Name: Advisory Committee on 

Interdisciplinary, Community-Based 

Linkages (ACICBL). 

Dates and Times: January 27, 2011, 

8:30 a.m. to 5 p.m., EST. January 28, 

2011, 8:30 a.m. to 4 p.m., EST. 

Place: Hilton Washington DC/ 

Rockville Executive Meeting Center, 

1750 Rockville Pike, Rockville, MD 

20852. Telephone: 301–468–1100. 

Status: The meeting will be open to 

the public. 

Purpose: The members of the ACICBL 

will advance the planning required to 

develop their 11th Annual Report for 

the Secretary of the Department of 

Health and Human Services (the 

Secretary) and Congress, using the 

working topic, Continuing Education, 

Professional Development and Lifelong 

Learning for the 21st Century Health 

Care Workforce. The meeting will 

provide the planning and writing subcommittees with the opportunity to 

review the urgent issues related to the 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 248 / Tuesday, December 28, 2010 / Notices 81625 

training programs, identify resources 

that will address the gaps and further 

strengthen the outcomes from these 

efforts, examine testimony from the 

experts in the field, and offer 

recommendations for improvement of 

these training programs to the Secretary 

and the Congress. 

Agenda: The ACICBL agenda includes 

an overview of the Committee’s general 

business activities, an orientation for the 

eight newly appointed members, 

presentations by and dialogue with 

experts, and discussion sessions specific 

to the development of recommendations 

to be addressed in the 11th Annual 

ACICBL Report. Agenda items are 

subject to change as dictated by the 

priorities of the Committee. 

SUPPLEMENTARY INFORMATION: Requests 

to make oral comments or to provide 

written comments to the ACICBL should 

be sent to Dr. Joan Weiss, Designated 

Federal Official at the contact 

information below. Individuals who 

plan to attend the meeting and need 

special assistance should notify Dr. 

Weiss at least 10 days prior to the 

meeting, using the address and phone 

number below. Members of the public 

will have the opportunity to provide 

comments at the meeting. 

FOR FURTHER INFORMATION CONTACT: 

Anyone requesting additional details 

should contact Dr. Joan Weiss, 

Designated Federal Official within the 

Bureau of Health Professions, Health 

Resources and Services Administration. 

Dr. Weiss may be reached by one of the 

three following methods: (1) Via written 

request to: Dr. Joan Weiss, Designated 

Federal Official, Bureau of Health 

Professions, Health Resources and 

Services Administration, Parklawn 

Building, Room 9–36, 5600 Fishers 

Lane, Rockville, Maryland 20857; (2) via 

telephone at (301) 443–6950; or (3) via 

e-mail at jweiss@hrsa.gov. In the 

absence of Dr. Weiss, CAPT Norma J. 

Hatot, Senior Nurse Consultant, may be 

contacted via telephone at (301) 443– 

2681 or by e-mail at nhatot@hrsa.gov. 

Dated: December 21, 2010. 

Robert Hendricks, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–32560 Filed 12–27–10; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Hesperetin Therapy for Metabolic 

Syndrome and Insulin Resistance 

Description of Technology: 

Hesperidin is a flavonoid compound 

found in citrus fruits. Large 

epidemiological studies have linked 

increased consumption of flavonoidrich foods, such as citrus, with reduced 

cardiovascular morbidity and mortality. 

Investigators from the National Center 

for Complementary and Alternative 

Medicine have demonstrated that 

administration of oral hesperidin to 

patients with metabolic syndrome 

attenuates biomarkers of inflammation 

and improves blood vessel relaxation, 

lipid cholesterol profiles, and insulin 

sensitivity when compared to controls. 

Thus, hesperidin and its active aglycone 

form, hesperetin, may be effective 

agents for the treatment of diabetes, 

obesity, metabolic syndrome, 

dyslipidemias, and their cardiovascular 

complications including hypertension, 

atherosclerosis, coronary heart disease, 

and stroke. This technology discloses 

methods for using a hesperetin 

composition to treat metabolic 

syndrome and insulin resistance. 

Applications: Therapeutics for 

metabolic syndrome and insulin 

resistance. 

Development Status: Clinical trial 

data available. 

Inventors: Michael J. Quon and 

Ranganath Muniyappa (NCCAM). 

Publications: Manuscript in 

preparation. 

Patent Status: U.S. Provisional 

Application No. 61/369,229 filled 30 

July 2010 (HHS Reference No. E–148– 

2010/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Tara L. Kirby, 

Ph.D.; 301–435–4426; 

kirbyt@mail.nih.gov. 

Substituted Triazine and Purine 

Compounds for the Treatment of 

Chagas Disease and African 

Trypanosomiasis 

Description of Technology: Parasitic 

protozoa are responsible for a wide 

variety of infections in both humans and 

animals. Trypanosomiasis poses health 

risks to millions of people across 

multiple countries in Africa and North 

and South America. Visitors to these 

regions, such as business travelers and 

tourists, are also at risk for contracting 

parasitic diseases. There are two types 

of African trypanosomiasis, also known 

as sleeping sickness. One type is caused 

by the parasite Trypanosoma brucei 

gambiense, and the other is caused by 

the parasite Trypanosoma brucei 

rhodesiensi. If left untreated, African 

sleeping sickness results in death. 

Chagas disease, caused by Trypanosoma 

cruzi (T. cruzi), affects millions of 

people in Mexico and South and Central 

America. Untreated, Chagas disease 

causes decreased life expectancy and 

can also result in death. 

The subject invention covers novel 

triazine and purine compounds that are 

inhibitors of key proteases (cruzain and 

Rhodesian) of the parasites 

Trypanosoma brucei rhodesiensi and 

Trypanosoma cruzi, respectively. 

Applications: Prophylactic and 

therapeutic treatment of African 

trypanosomiasis and Chagas disease. 

Advantages 

• Novel compounds against the 

cysteine proteases, cruzain and 

rhodesain. 

• Compounds possess low nanomolar 

inhibitory potential against cruzain and 

rhodesain. 

Development Status: In vitro and in 

vivo data are available upon request and 

upon execution of an appropriate 

confidentiality agreement. 

Inventors: Craig J. Thomas et al. 

(NHGRI). 

Related Publication: BT Mott et al. 

Identification and optimization of 

inhibitors of Trypanosomal cysteine 


emcdonald on DSK2BSOYB1PROD with NOTICES